Business

May 19, 2014

Merck elects not to develop Chimerix's HIV drug

Merck has opted out of developing an HIV drug from Chimerix. The small Durham drug developer had sold Merck exclusive rights 2 years ago with a potential $151 million payoff, which won't happen now.

Related content

Comments

Videos

Editor's Choice Videos